Skip to main content
Premium Trial:

Request an Annual Quote

PCLS, Genesys Partner to Offer Proteomics Lung Cancer Test

NEW YORK (GenomeWeb News) – Physician's Choice Laboratory Services today announced a partnership to offer Genesys Biolabs' proteomic test for screening and the early detection of lung cancer.

The test, called PAULA's Test, short for Protein Assay Using Lung Cancer Analytes, measures three tumor proteins and an additional analyte that are commonly associated with lung cancer. The blood-based test is analyzed in Genesys' CLIA-certified laboratory.

Citing statistics from the American Cancer Society, PCLS said that about 228,190 new cases of lung cancer will be diagnosed this year in the US with 159,480 lung cancer-associated deaths.

PCLS, based in Rock Hill, SC, provides toxicology and genetics testing services. Genesys is a division of 20/20 GeneSystems and develops proteomic-based diagnostics tests with a focus on cancer. It is headquartered in Rockville, Md.

Financial and other terms of the agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more